A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis

British Journal of Rheumatology

Volumn 35, Issue SUPPL. 1, 1996, Pages 17-21

  Reginster, J Y ^a,b,d   Distel, M ^c   Bluhmki, E ^c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b GEORGETOWN UNIVERSITY   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

COX 2 inhibition; Meloxicam; Non steroidal anti inflammatory drugs; Rheumatoid arthritis

Indexed keywords

MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BODY WEIGHT; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL SYMPTOM; GRIP STRENGTH; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MORNING STIFFNESS; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SKIN DISEASE; URINARY TRACT DISEASE; VISUAL DISORDER;

EID: 0029870733     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.suppl_1.17     Document Type: Article

References (14)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231:232-5.
2. Vane J. Towards a better aspirin. Nature 1994;367:215-6.
3. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995;44:423-33.
4. Engelhardt G. Meloxicam: a potent inhibitor of COX-2. Data presented at 9th International Conference on Prostaglandins and Related Compounds. Florence, Italy, June 6-10,1994, p. 82.
5. Huskisson EC, Narjes H, Bluhmki E. Efficacy and tolerance of meloxicam, a new NSAID, in daily oral doses of 15, 30 and 60 mg in comparison to 20 mg piroxicam in patients with rheumatoid arthritis. Scand J Rheumatol 1994;Suppl 98:abstractno. 115.
6. Ropes MW, Bennet GA, Cobb S, Jaox R, Jessar RA. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958;9:175-6.
7. Ritchie DM, Boyle JA, McInness JM et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;37:393-406.
8. Furst DE. Synovial fluid kinetics of non-steroidal anti-inflammatory drugs: basis for variability in response. Agents Actions 1985;Suppl 17:65-78.
9. Larkai EN, Lacey Smith J, Lidsky MD, Sessoms SL, Graham DY Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989;11:158-62.
10. Coles LS, Fries JF, Kraines RG, Roth SH. From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1983;74:820-8.
11. Lemmel EM, Bolten W, Burgos-Vargas R et al. A double-blind placebo controlled study of 7.5 mg and 15 mg of meloxicam in patients with rheumatoid arthritis (RA). Scand J Rheumatol 1994;Suppl 98:abstract no. 111.
12. Lund B, Distel M, Bluhmki E. A double-blind placebo controlled study of three different doses of meloxicam in patients with osteoarthritis (OA) of the knee. Scand J Rheumatol 1994;Suppl 98:abstract no. 117.
13. Lequesne M. Methodology issues in the evaluation of NSAID in inflammatory rheumatic diseases. J Rheumatol 1990;17(suppl. 20):25-8.
14. Gøtzsche PC. Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. J Clin Epidemiol 1990;43:1313-8.